Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells

被引:37
作者
Wong, C
Waibel, R
Sheets, M
Mach, JP
Finnern, R
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Anesthesia, San Francisco, CA 94110 USA
[2] Paul Scherrer Inst, CH-5232 Villigen, Switzerland
[3] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland
关键词
human scFv; mucin MUC-1; phage display; cell surface selection; tumour immunotherapy;
D O I
10.1007/s002620100174
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
New anti-cancer agents are being developed that specifically recognise tumour eels. Recognition is dependent upon the enhanced expression of antigenic determinants on the surface of tumour cells. The tumour exposure and the extracellular accessibility of the mucin MUC-1 make this marker a suitable target for tumour diagnosis and therapy. We isolated and characterised six human scFv antibody fragments that bound to the MUC-1 core protein, by selecting a large naive human phage display library directly on a MUC-1-expressing breast carcinoma cell line. Their binding characteristics have been studied by ELISA, FAGS and indirect immunofluorescence. The human scFv antibody fragments were specific for the tandem repeat region of MUG-I and their binding is inhibited by soluble antigen. Four human scFv antibody fragments (M2, M3, M8, M12) recognised the hydrophilic PDTRP region of the MUC1 core protein, which is thought to be an immunodominant region. The human scFv antibody fragments were stable in human serum at 37 degreesC and retained their binding specificity. For imaging or targeting to tumours over-expressing MUC-1, it might be feasible to use these human scFv, or multivalent derivatives, as vehicles to deliver anti-cancer agents.
引用
收藏
页码:93 / 101
页数:9
相关论文
共 30 条
[1]   Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries [J].
Amersdorfer, P ;
Wong, C ;
Chen, S ;
Smith, T ;
Deshpande, S ;
Sheridan, R ;
Finnern, R ;
Marks, JD .
INFECTION AND IMMUNITY, 1997, 65 (09) :3743-3752
[2]   Making the most of mucin: A novel target for tumor immunotherapy [J].
BarrattBoyes, SM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 43 (03) :142-151
[3]   THE PROGNOSTIC VALUE OF THE MONOCLONAL-ANTIBODIES HMFG1 AND HMFG2 IN BREAST-CANCER [J].
BERRY, N ;
JONES, DB ;
SMALLWOOD, J ;
TAYLOR, I ;
KIRKHAM, N ;
TAYLORPAPADIMITRIOU, J .
BRITISH JOURNAL OF CANCER, 1985, 51 (02) :179-186
[4]   SINGLE-CHAIN ANTIGEN-BINDING PROTEINS [J].
BIRD, RE ;
HARDMAN, KD ;
JACOBSON, JW ;
JOHNSON, S ;
KAUFMAN, BM ;
LEE, SM ;
LEE, T ;
POPE, SH ;
RIORDAN, GS ;
WHITLOW, M .
SCIENCE, 1988, 242 (4877) :423-426
[5]   A SURFACE EXPRESSION VECTOR FOR ANTIBODY SCREENING [J].
BREITLING, F ;
DUBEL, S ;
SEEHAUS, T ;
KLEWINGHAUS, I ;
LITTLE, M .
GENE, 1991, 104 (02) :147-153
[6]  
BROOKS SC, 1973, J BIOL CHEM, V248, P6251
[7]  
DeNardo SJ, 1997, J NUCL MED, V38, P1180
[8]  
DOMENECH N, 1995, J IMMUNOL, V155, P4766
[9]   Human autoimmune anti-proteinase 3 scFv from a phage display library [J].
Finnern, R ;
Pedrollo, E ;
Fisch, I ;
Wieslander, J ;
Marks, JD ;
Lockwood, CM ;
Ouwehand, WH .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1997, 107 (02) :269-281
[10]  
FONTENOT JD, 1993, CANCER RES, V53, P5386